遺伝子治療の市場規模、シェア、動向分析レポート：適応症別、ベクタータイプ別、投与経路別、地域別、セグメント予測、2024年～2030年

遺伝子治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の遺伝子治療市場は2024年から2030年にかけて18.88%のCAGRを記録し、2030年までに182億米ドルに達すると予測されています。

市場開拓の背景には、遺伝子治療に基づく発見件数の増加、この分野への投資の増加、遺伝子治療製品の承認率の上昇があります。WHOによると、2025年までに毎年10～20の新しい細胞療法と遺伝子療法が承認される見込みです。

組換えDNA技術の継続的な開発により、今後数年間は遺伝子治療の効率が高まると予想されています。したがって、遺伝子組換えDNA技術における継続的な進歩は、遺伝子治療の臨床試験数を拡大すると予想されます。主に、このような進歩は、製品の研究開発を強化するための様々な遺伝子編集ツールや発現システムの文脈で起こっています。CRISPR/Cas9ヌクレアーゼ、ZFN、TALENの登場は、簡単かつ正確なゲノム編集を可能にしました。その結果、近年、遺伝子編集分野では多くの研究活動が行われており、遺伝子治療市場の成長にも影響を及ぼすと予想されています。

遺伝子治療市場の成長は、がんの有病率の増加から大きな恩恵を受けると予想されます。年間がん患者数と関連死亡者数の継続的な増加により、強固な治療ソリューションの開発が不可欠であることが強調されています。2020年には、世界中で約1,810万人のがん患者が新たに発生しました。このうち930万人が男性で、880万人が女性です。腫瘍遺伝子研究の継続的な発展は、がんに関連する分子シグネチャーに関する実質的な情報を提供し、ひいてはがん治療薬の進行中の臨床試験をサポートすると期待されています。

強固な疾患治療に対する需要が高まる中、企業はゲノムレベルで疾患の原因を標的とする効果的な遺伝子治療の研究開発を加速させることに注力しています。.さらに米国FDAは、製品製造に関する多くの政策を通じて、この分野のイノベーションを常に支援しています。2020年1月、FDAは安全で効率的な製品の製造と臨床開発に関する6つの最終ガイドラインを発表しました。

さらに、細胞治療や遺伝子治療のための施設拡張は、遺伝子治療市場の成長を促進する主な要因の1つです。遺伝子治療製造のためのいくつかの自社施設やCDMOは、生産能力を強化するための投資を開始しており、その結果、市場プレーヤーにとって有利な機会が生まれると予想されています。例えば、2022年4月、FDAはノバルティスのノースカロライナ州ダーラムの施設の商業認可を承認しました。この認可により、170,000平方フィートの施設は、ゾルゲンマの製造、試験、販売、および現在および今後の臨床試験用の治療製品の製造を許可されました。

遺伝子治療市場レポートハイライト

• AAVセグメントは2023年に22%の大幅な売上貢献を示します。複数のバイオファーマ企業が、AAVベースの遺伝子治療製品開発のためにウイルスベクタープラットフォームを提供しています。
• 適応症別では、脊髄性筋萎縮症（SMA）分野が2023年に46.8%のシェアで市場を独占しました。脊髄性筋萎縮症はまれな疾患ではあるが、乳幼児期の致死的な遺伝性疾患としては最も一般的なもの一つです。
• 予測期間中、最も速いCAGR 38.3%を記録すると予測されるのは、B型サラセミア/SCD分野です。SCDおよびB-サラセミアに対する遺伝子治療は、遺伝子改変造血幹細胞の移植に基づいています。
• 2023年には北米が65.2％の最大売上シェアで市場を独占しました。この地域は、予測期間中に承認件数と収益で遺伝子治療の最大のルーチン・メーカーになると予想されます。
• 欧州は、2024年から2030年にかけて最も急成長する地域セグメントと推定されます。これは、アンメット・メディカル・ニーズを抱える人口が多いことと、希少だがますます蔓延している疾患の治療における新規技術への需要が高まっていることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
• 業界分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 投与経路別ビジネス分析

• 遺伝子治療市場：投与経路別変動分析
• 静脈内
• その他

第5章 適応症別ビジネス分析

• 遺伝子治療市場：適応症別変動分析
• 急性リンパ性白血病
• 遺伝性網膜疾患
• 大細胞型B細胞リンパ腫
• 悪性黒色腫（病変）
• ベータサラセミア重症型/鎌状赤血球症（ScD）
• 脊髄性筋萎縮症（SMA）
• その他

第6章 ベクタータイプ別ビジネス分析

• 遺伝子治療市場：ベクタータイプ別変動分析
• レンチウイルスベクター
• アデノ随伴ウイルス（Aav）ベクター
• レトロウイルスとガンマレトロウイルス
• 改変単純ヘルペスウイルス
• アデノウイルスベクター
• その他

第7章 地域別ビジネス分析

• 遺伝子治療市場シェア：地域別、2023年と2030年
• 北米
• 欧州
• アジア太平洋
• 世界のその他の地域

第8章 競合情勢

• 企業分類
• 戦略マッピング
• 企業市況分析、2023年
• 企業プロファイル
  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche
  • Gilead Sciences, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Legend Biotech.
  • BioMarin.
  • uniQure NV
  • Merck &Co.
  • Sarepta Therapeutics, Inc.
  • Krystal Biotech, Inc
  • CRISPR Therapeutics.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Tables
• Table 3 List of Secondary Sources
• Table 4 List of Abbreviations
• Table 5 Global Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 6 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 7 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 8 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
• Table 9 North America Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
• Table 11 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 12 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 13 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 15 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 16 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 17 Canada Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 18 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 19 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
• Table 20 Europe Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 21 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 22 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 23 Germany Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 24 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 25 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 26 UK Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 27 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 28 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 29 Switzerland Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 30 Switzerland Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 31 Switzerland Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 36 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 37 China Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 38 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 39 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 40 Japan Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 41 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 42 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 43 South Korea Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 44 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 45 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 46 Australia Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 47 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
• Table 48 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
• Table 49 RoW Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
• Table 50 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Market Formulation & Validation
• Fig. 5 Gene Therapy Market Segmentation
• Fig. 6 Porter's Five Forces Analysis
• Fig. 7 Regional Marketplace: Key Takeaways
• Fig. 8 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
• Fig. 9 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
• Fig. 10 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
• Fig. 11 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
• Fig. 12 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
• Fig. 13 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
• Fig. 14 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
• Fig. 15 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
• Fig. 16 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
• Fig. 17 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
• Fig. 18 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
• Fig. 19 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
• Fig. 20 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
• Fig. 21 Global Gene Therapy Market for Intravenous, 2018 - 2030 (USD Million)
• Fig. 22 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
• Fig. 23 Regional Outlook, 2022 & 2030
• Fig. 24 North America Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 25 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 26 Canada Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 27 Europe Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 28 Germany Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 29 UK Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 30 Switzerland Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 31 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 32 Japan Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 33 China Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 34 Australia Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 35 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
• Fig. 36 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)

Gene Therapy Market Growth & Trends:

The global gene therapy market is expected to reach USD 18.20 billion by 2030, registering a CAGR of 18.88% from 2024 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights:

• The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
• By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
• The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and B-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
• North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
• Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Indication
  • 1.2.2. Route of Administration
  • 1.2.3. Vector Type
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
• 1.7. Primary Research
• 1.8. Information or Data Analysis
• 1.9. Market Formulation & Validation
• 1.10. Market Model
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Robust Gene Therapy Pipeline
    • 3.2.1.2. Introduction Of Technological Advancements
    • 3.2.1.3. Increasing Investment From Companies And Partnerships
    • 3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Absence Of Effective Diagnosis Framework
    • 3.2.2.2. High Prices Of Gene Therapy
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
    • 3.2.3.2. Facility Expansion For Cell And Gene Therapies
    • 3.2.3.3. Technological Advancements In Manufacturing Vectors
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Route of Administration Business Analysis

• 4.1. Gene Therapy Market: Route of Administration Movement Analysis
• 4.2. Intravenous
  • 4.2.1. Intravenous Market, 2018 - 2030 (USD Million)
• 4.3. Others
  • 4.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Indication Business Analysis

• 5.1. Gene Therapy Market: Indication Movement Analysis
• 5.2. Acute Lymphoblastic Leukemia
  • 5.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
• 5.3. Inherited Retinal Disease
  • 5.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
• 5.4. Large B-Cell Lymphoma
  • 5.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
• 5.5. Melanoma (lesions)
  • 5.5.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
• 5.6. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
  • 5.6.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
• 5.7. Spinal Muscular Atrophy (SMA)
  • 5.7.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Vector Type Business Analysis

• 6.1. Gene Therapy Market: Vector Type Movement Analysis
• 6.2. Lentiviral Vectors
  • 6.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
• 6.3. Adeno-Associated Viral (Aav) Vectors
  • 6.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
• 6.4. RetroVirus & gamma RetroVirus
  • 6.4.1. RetroVirus & gamma RetroVirus market, 2018 - 2030 (USD Million)
• 6.5. Modified Herpes Simplex Virus
  • 6.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
• 6.6. Adenovirus Vectors
  • 6.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Gene Therapy Market Share By Region, 2023 & 2030
• 7.2. North America
  • 7.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target disease prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target disease prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target disease prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Mexico Gene Therapy Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target disease prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target disease prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.3.4. Switzerland
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target disease prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Switzerland Gene Therapy Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target disease prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target disease prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
  • 7.4.4. Australia
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target disease prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
• 7.5. Rest of the world
  • 7.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Company Profiles
  • 8.4.1. Amgen Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Novartis AG
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. F. Hoffmann-La Roche
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Gilead Sciences, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. bluebird bio, Inc.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Bristol-Myers Squibb Company
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Legend Biotech.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. BioMarin.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. uniQure N.V.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Merck & Co.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Sarepta Therapeutics, Inc.
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. Krystal Biotech, Inc
    • 8.4.12.1. Overview
    • 8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Strategic Initiatives
  • 8.4.13. CRISPR Therapeutics.
    • 8.4.13.1. Overview
    • 8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.13.3. Product Benchmarking
    • 8.4.13.4. Strategic Initiatives